ALX Oncology acquires ScalmiBio to expand pipeline
ALX Oncology acquires ScalmiBio to expand pipeline
58.02MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00166B1052
CUSIP
00166B105
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
2.59
Dividend Share
-
Dividend Yield
-
Earnings Share
-2.97
Wall Street Target Price
4.04
EPS Estimate Current Year
-1.72
EPS Estimate Next Year
-1.39
EPS Estimate Current Quarter
-0.78
EPS Estimate Next Quarter
-0.77
Most Recent Quarter
-
Revenue TTM
0
Gross Profit TTM
107,000
EBITDA
-159,012,000
Profit Margin
0.00%
Return On Assets TTM
-49.25%
Return On Equity TTM
-98.94%
Revenue Per Share TTM
0
Qtly Revenue Growth YOY
-100.00%
Diluted Eps TTM
-2.97
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
5906.2383
Price Book MRQ
0.4549
Enterprise Value Revenue
4254
Enterprise Value EBITDA
-2
160.66
2.91%82.78
2.49%96.32
2.13%640.30
0.20%462.26
0.03%250.04
0.02%697.42
0.00%190.00
0.00%120.78
-1.52%679.74
-0.00%